Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afatinib plus cisplatin and 5-fluorouracil as first-line therapy in inoperable gastric or gastroesophageal junction cancer
2011-006198-25Phase 2Completed
- Sponsor
- HeCOG
- Start
- Oct 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of afatinib in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by HeCOG. Primary endpoint: Objective Response Rate (ORR). Started Oct 2012; status: completed.
02
Drugs
afatinib
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2011-006198-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-006198-25.